By ONN Staff

Adding atezolizumab to adjuvant FOLFOX halved the risk of recurrence or death in ATOMIC, with more grade 3 to 4 adverse events.

Real-time check-ins from patients with MBC showed quality of life dipped when depression, anxiety, or fatigue rose above usual levels.

FDA approves tucatinib maintenance with trastuzumab and pertuzumab for HER2+ breast cancer based on HER2CLIMB-05.

Five-week hypofractionated radiation after prostatectomy showed similar 5-year cancer control and quality of life but more grade 3 urinary toxicity.

FDA approves pirtobrutinib for untreated CLL/SLL without 17p deletion based on BRUIN CLL-313 data. Read key nursing safety takeaways.

Most oral blood cancer drug prescriptions were first rejected by insurers, and fill rates fell sharply when out-of-pocket costs topped $175.

Solid tumor history, cardiopulmonary symptom burden, and age-dependent chemo intensity predicted 30-day readmission or death after AML induction.

Take our quick survey to help Oncology Nursing News improve how we deliver updates across web, video, email, social media, and podcasts.

An FDA advisory panel voted to approve GRAIL's Galleri multi-cancer early detection test for adults 50+. Read key oncology nursing takeaways.

FDA approves belzutifan with lenvatinib for advanced clear cell RCC after PD-1/PD-L1 inhibitor failure. Review LITESPARK-011 data and nursing takeaways.

From ICN 2026, Heather Jackson and Ashley Johnson detail APP breast care access models, global cancer pain barriers, and burnout mitigation tactics.

FDA approves lirafugratinib (Lyrfigtu) for FGFR2+ cholangiocarcinoma. Review REFOCUS trial data, 70 mg daily dosing, and nursing safety guidelines.

A nurse-led support program significantly reduces death anxiety in women with breast cancer on hormonal therapy, study finds.

FDA approves lutetium lu 177 dotatate (Bravnetsa) as bioequivalent to Lutathera for GEP-NETs. Review key nursing takeaways and safety guidelines.

FDA approves sNDA for taletrectinib (Ibtrozi) in ROS1+ NSCLC with updated DOR of nearly 50 months.

KEYNOTE-564 data show adjuvant pembrolizumab maintains DFS and OS benefits in ccRCC. Review key nursing takeaways and safety outcomes.

NCCN survey data show 100% of cancer centers face drug shortages, with ifosfamide and carboplatin critical.

FDA approves cabozantinib capsules for RCC, HCC, and epNET. Review key dosing conversions and safety guidelines for oncology nursing practice.

FDA grants accelerated approval to sevabertinib (Hyrnuo) for HER2 TKD-mutant non-squamous NSCLC, expanding access to treatment-naive patients.

FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for adult patients with ESR1-mutated HR+/HER2- advanced breast cancer.

Phase 3 NRG-GU005 trial shows SBRT limits bowel complications and fatigue compared to MH-IMRT, but does not improve disease-free survival rates.

Study of breast cancer survivors shows that depression and stress, rather than cardiac function decline, are the primary drivers of long-term fatigue.

FDA approves rusfertide (Mimrylo), a first-in-class hepcidin mimetic that regulates iron to control erythrocytosis in patients with polycythemia vera.

New ASCO living guideline establishes standard-of-care frameworks for recurrent ovarian cancer, highlighting biomarkers and treatment sequencing.

Oncology nurses share high-level strategies for advanced RCC therapy, focusing on managing hypertension, diarrhea, and fatigue in the frontline.

FDA approves BESREMi (ropeginterferon alfa-2b-njft) as the first new treatment option for essential thrombocythemia in nearly three decades.

A new study shows physical activity increases tumor-killing T cells and reduces suppressive Tregs in obese lung environments, boosting outcomes.

Topline Phase 3 results show individualized mRNA therapy intismeran plus Keytruda significantly improves recurrence-free survival in melanoma.

FDA approves daraxonrasib, a first-in-class daily oral RAS inhibitor, doubling survival in metastatic pancreatic adenocarcinoma patients.

FDA approves two Ziihera combinations as a first-line treatment standard for adults with HER2-positive advanced gastroesophageal adenocarcinoma.